GlassScriptPhysician profile
Jeremiah Whittington
NPI 1477554939
$2,161.49
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,958 · 2020: $185 · 2022: $18.84.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,100.00 | 2019 | |
| Abbvie INC. | $370.79 | 2019-2020 | |
| Lupin INC. | $254.66 | 2019-2020 | |
| Therapeuticsmd, INC. | $140.89 | 2019 | |
| Duchesnay USA Incorporated | $117.51 | 2019 | |
| Aspira Women'S Health INC | $73.26 | 2020 | |
| Ferring Pharmaceuticals INC. | $30.39 | 2019 | |
| Exeltis, USA INC. | $26.91 | 2019 | |
| Myovant Sciences INC. | $18.84 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.19 | 2019 | |
| Allergan, INC. | $14.05 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremiah Whittington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.